2024-07-03 06:19:10 ET
Summary
- Healthcare capex demand has supported healthy order growth at Siemens Healthineers, as the company leverages new innovative platforms in Imaging (MRI, CT) and radiation oncology (Varian).
- The Street wants margin leverage and order growth in FQ3'24, and I think there's a good chance of getting both.
- Diagnostics still needs a lot of work to become more competitive, and a rumored sale/spin may be a better option.
- Imaging is looking strong as the company is still in the early days of practice-changing technologies like photon-counting CT.
- Revenue growth in the range of 5% to 6% and EBITDA margins of 20%+ can still support further gains.
Despite worries about hospital budgets, healthcare capex has held up pretty well over the last 18 months, and Siemens Healthineers ( OTCPK:SMMNY ) (SHLG.DE) has leveraged innovative new products into that healthy market to continue generating more than respectable revenue growth, albeit with some unexpected margin challenges along the way....
Read the full article on Seeking Alpha
For further details see:
Siemens Healthineers: Softer Orders A Risk, But The Story Remains Sound